UNSPSC 51281671: Spectinomycin sulfate tetrahydrate

This classification denotes an aminoglycoside antibiotic C14H24N2O7.4H2O.H2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier YS91P54918, chemically known as (2r-(2.alpha.,4a.beta.,5a.beta.,6.beta.,7.beta.,8.beta.,9.alpha.,9a.alpha.,10a.beta.))-decahydro-4a,7,9-trihydroxy-2-methyl-6,8-bis(methylamino)-4h-pyrano(2,3-b)(1,4)benzodioxin-4-one sulfate tetrahydrate, but more generally known as spectinomycin sulfate tetrahydrate, which bears US NIH Compound Identifier 64770.

UNSPSC 51281671 Spectinomycin sulfate tetrahydrate is a Commodity code representing pharmaceutical active ingredients and finished drug products procured by state and local health departments and counties for public health and emergency response programs. State and local governments buy finished pharmaceutical products—antibiotics, overdose-reversal agents, and drug deactivation systems—under this code to support disease prevention, treatment, and community health initiatives. The issuing bodies are primarily state departments of public health and county health agencies conducting competitive bidding through cooperative purchasing agreements and invitation-for-bid processes.

Recent opportunities show activity across Florida and Illinois. The Illinois Department of Public Health awarded a pharmaceutical warehouse piggyback contract to Chartwell Rx LLC on August 28, 2026, through the MMCAP Infuse cooperative purchasing consortium for Doxycycline Hyclate 100mg tablets and Ciprofloxacin Hydrochloride 500mg tablets—a $2.99 million award over 12 months with two optional renewal years. Seminole County, Florida posted an invitation for bid (IFB 60459723LAS) on June 30, 2026, seeking 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with quarterly deliveries to the county's Community Health Building in Sanford, under a two-year initial term with one-year renewal option; bidders were required to submit electronically by July 26, 2026. Both procurements emphasize fixed-fee pricing, vendor compliance with drug-free workplace and E-Verify requirements, and competitive award to the lowest responsive bidder.